Loading viewer...
investor_presentation
Format: PDF investor_presentation
Megaport Limited's 2Q FY24 quarterly investor presentation detailing financial performance and operational highlights. The update shows strong cash flow turnaround with net cash flow of $6.9M and operating cash flow of $15.2M, alongside revenue growth and strategic expansion in direct sales roles across North America.
investor_presentation
14 Pages
investor_presentation
21 Pages
Balaxi Pharmaceuticals Limited
Karyopharm XPOVIO FDA Accelerated Approval DLBCL 2020
investor_presentationinvestor_presentation
25 Pages
Karyopharm Therapeutics Inc.